Background: It is unclear whether the overall effectiveness and safety of direct oral
anticoagulants (DOACs) are consistent in patients with nonvalvular atrial fibrillation (AF) and …

Background and Purpose—Obesity is a risk factor for all-cause and cardiovascular death
but, despite this, an inverse relationship between overweight or obesity and a better …

Abstract Background Direct oral anticoagulants (DOACs) are preferred over warfarin for the
treatment of venous thromboembolism (VTE) as well as atrial fibrillation (AF). The efficacy …

Background Data on the relationship between body mass index (BMI), thromboembolic
events (TEE) and bleeding in patients with atrial fibrillation (AF) are controversial, and further …

Purpose We conducted a multicenter real-world study in China to assess the association
between body mass index (BMI) and clinical outcomes in patients with atrial fibrillation (AF) …

Background Direct‐acting oral anticoagulants are now the preferred method of
anticoagulation in patients with atrial fibrillation. Limited data on efficacy and safety of these …

Purpose Oral anticoagulants are crucial for preventing systemic thromboembolism in atrial
fibrillation (AF), with guidelines preferring non-vitamin K antagonist oral anticoagulants …

Background Limited clinical data exist describing the use of direct oral anticoagulants
(DOACs) in patient with extreme body weight. Thus, the International Society of Thrombosis …

Purpose: There is limited clinical data evaluating anticoagulation with the direct oral
anticoagulants (DOACs) in morbidly obese patients. We sought to examine the efficacy in …

Background There is a paucity of evidence regarding the effects of non-vitamin K antagonist
oral anticoagulants (NOACs) in underweight patients with atrial fibrillation (AF). Objective …